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A B S T R A C TObjective: To evaluate the direct medical cost of hospital admissions
for patients with varicella (i.e., chickenpox) to assess the cost burden
of varicella from a health care perspective for ultimate use in health
economics studies in Turkey. Methods: Records of children hospital-
ized with varicella at the Bakirkoy Maternity and Children’s Hospital
between November of 2006 and June of 2011 were reviewed. Reasons
for hospitalization, types of varicella-associated complications, and
direct medical cost of hospitalization were noted. Patients with
underlying risk factors were excluded. Data obtained from one
hospital were used to estimate the national cost of the disease.
Results: During the 4.5-year study period, 234 patients were hospi-
talized with varicella. Of these cases, 48 (20%) children previously ill
with underlying cancers or chronic diseases were excluded from the
study. Ultimately, 186 previously healthy children (age range: 14 days
to 159 months, median age: 14 months) were included. The mainsee front matter Copyright & 2013, International S
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niversity, Adnan Menderes Bulvarı Vatan caddesireasons for hospitalization were complications related to varicella
(79%), the most frequent of which was skin and soft tissue infections,
followed by neurological complications and pneumonia. The median
cost of hospitalization per patient was US $283, 50% of which was
attributed to medication costs. The annual cost for varicella hospital-
izations in Turkey was estimated at US $396,200. Conclusions: A
signiﬁcant number of healthy children are hospitalized for varicella
and associated complications. Descriptions of these complications
and their related costs provide important data for cost-effectiveness
studies for decisions about the inclusion of the varicella vaccine in a
childhood vaccination program.
Keywords: child, complications, cost, varicella.
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Varicella, otherwise known as chickenpox, that is, the primary
manifestation of a varicella zoster virus (VZV) infection, is gen-
erally mild; indeed, severe complications are seldom reported in
immunocompetent children [1]. Nevertheless, hospitalizations
due to varicella do occur in otherwise healthy children, thereby
producing an economic burden on the health care system [2].
Worldwide, the reported incidence of varicella-related hospital-
izations involving children varies widely, that is, from 0.9 to 29.4/
100,000, depending on the geographic setting and hospital admis-
sion policies [3–5]. In Turkey, the exact incidence is unknown
because varicella is not on the list of tracked diseases; however,
estimates indicate that the rate is 6.3/100,000 [6].
A safe and effective vaccine against varicella was developed in
1970 and has been made a recommended part of childhood
vaccination programs in several countries. Countries with routine
childhood varicella vaccinations have seen a positive effect on
disease prevention and control [7–13]. In the United States, the
annual varicella-related hospitalization rate decreased from 0.5 per
10,000 in 1993 to 0.13 per 10,000 in 2001. The incidence of varicellahas also decreased in nonvaccinated groups, including adults and
infants who are too young to be vaccinated, thereby suggesting a
strong herd protection effect [7–10]. A widespread varicella vacci-
nation program, however, has not yet been introduced everywhere,
especially in developing countries.
The health economics of a VZV immunization program is vital
for decisions on vaccine funding and has been studied in many
countries [14–17]. To facilitate the decision-making process
regarding the introduction of a vaccination program, each coun-
try needs to collect data on the incidence, complications, and cost
due to hospitalizations associated with the particular disease
under consideration. Surveillance of varicella complications is
also important to assess the potential impact of a vaccination
program. In Turkey, a few studies have evaluated complication
rates; however, knowledge about the cost of varicella hospital-
izations is quite limited. A more detailed investigation of the cost
burden of varicella from a health care perspective can be
accomplished by collecting data about the number and cost of
hospitalizations in a tertiary care hospital in Istanbul, which can
then be extrapolated to the whole country to estimate the
national burden of this disease.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ics, Division of Pediatric Infectious Diseases, School of Medicine,
34093 Fatih, Istanbul, Turkey.
Table 1 – Varicella-related hospitalized patients
with underlying illnesses.
Underlying illness n %
Malignancy
Acute lymphoblastic leukemia 14 29
Lymphoma 2 4.2
Rhabdomyosarcoma 1 2.1
Spinal tumor 1 2.1
Neuroblastoma 1 2.1
PNET 1 2.1
Metabolic
Type 1 diabetes mellitus 5 10.4
Congenital adrenal hyperplasia 2 4.2
Cystic ﬁbrosis 1 2.1
Graves’ disease 1 2.1
Niemann Pick 1 2.1
Hematologic
Hereditary spherocytosis 2 4.2
Diamond Blackfan anemia 1 2.1
Thalassemia major 1 2.1
Thrombasthenia 1 2.1
Factor 7 deﬁciency 1 2.1
Chronic ITP 2 4.2
Primary immunodeﬁciency
SCID 1 2.1
IgA deﬁciency 1 2.1
CVID 1 2.1
Cyclic neutropenia 1 2.1
Other 2 4.2
Other
Holoprosencephaly 1 2.1
CMV hepatitis, hyperphenylalaninemia 1 2.1
Echinococcal cyst 1 2.1
Total 48 100
CMV, cytomegalovirus; CVID, common variable immunodeﬁ-
ciency; IgA, immunoglobulin A; ITP, idiopathic thrombocytopenic
purpura; PNET, primitive neuroectodermal tumor; SCID, severe
combined immunodeﬁciency.
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Study Design
In this retrospective cohort study, we reviewed the records of
children with varicella who were admitted to the Bakirkoy
Maternity and Children’s Educational and Treatment Hospital
(BEH) between November of 2006 and June of 2011. In Istanbul, a
majority of patients are treated at secondary and tertiary care
hospitals [18]. BEH is one of the main tertiary referral centers for
pediatric patients in which 40,000 patients are hospitalized and
over 500,000 patients are examined annually [19]. The population
of children aged younger than 15 years in Istanbul is 3,455,049,
that is, one-ﬁfth of the population under 15 in Turkey [20].
Data Collection
Enrollment in this study required a discharge diagnosis of
varicella or its associated complications as deﬁned by the Interna-
tional Classiﬁcation of Disease codes. Further detailed investigations
of medical records of patients hospitalized with varicella were
undertaken to avoid incorrect diagnoses. Data on the demo-
graphic features of the patients, their underlying conditions,
reasons for hospitalization, types of varicella-related complica-
tions, blood culture results, length of hospital stay, outcomes,
and costs were collected.
Hospital expenses noted in this study included the cost of the
prescribed drugs, doctor visits, nursing care, laboratory and
radiological diagnostic tests, bed stay, and other related charges.
The records of the patients logged hospital costs in the Turkish
lira and were converted into the US dollar.
Statistical Analysis
Version 16 of the Statistical Package for Social Sciences (SPSS for
Windows) was used for all statistical analyses. One-way analysis
of variance was used to compare continuous data among more
than two groups. Multiple comparisons were analyzed by using
Tukey’s honestly signiﬁcant difference post hoc test, while
Pearson’s correlation test was used to assess the relationships
among continuous variables.Results
Of the 684 children with varicella who were examined at BEH
during the study time period, 234 were hospitalized. Of these cases,
48 patients (i.e., 20%) had an underlying illness and were thus
excluded from the study (Table 1). Therefore, 186 previously healthy
children (i.e., 55.9% males) were included in this study. Considering
that BEH provides services to 15% of all children hospitalized in
Istanbul and 3% of all children hospitalized in Turkey, the annual
number of formerly healthy children younger than 15 years who are
hospitalized because of varicella in Turkey was estimated at 1400.
The median age of the patients with varicella in our study was
14 months (i.e., ranging from 14 days to 159 months). The highest
rate of hospitalization occurred in patients younger than age 3
years (i.e., 74.15%), of which 64.2% were younger than or equal to
age 1 year. The median length of hospital stay for this population
was 5 days. The majority of the cases were detected in the spring
and early summer months, with a peak in May (Fig. 1). The main
reasons for hospitalization were complications associated with
varicella (i.e., accounted for 79% of the admissions). Bacterial
superinfections involving the skin and soft tissues accounted for
32.6% of the admissions and were the most frequently observed
complications; this was followed by neurological complications
in 29.9% of the admissions and pneumonia in 21.7% of theadmissions (Table 2). The children who were hospitalized for
pneumonia were younger than those hospitalized with neuro-
logical complications (P o 0.05) (Fig. 2). Most outcomes were
favorable with exception to one child needing thoracal tube
insertion to treat empyema, one with abduscent nerve paralysis,
and one with cellulitis that resulted in severe scarring.
The median cost of hospitalization per patient was US $283, 50%
of which was attributed to medication costs (Table 3). The costs for
physician visits were lowest among the cost categories listed in
Table 3 because revisits are not billed in accordance with current
Turkish regulations. A positive correlation was observed between the
total costs and the age of the patients (r ¼ 0.27, P o 0.001). Costs for
hematological complications were higher than the costs for any of
the other complications. For the ﬁve patients with the highest total
costs, three had hematological complications and received blood
transfusions; for the remaining two, one had septicemia and the
other child had severe cellulitis that necessitated 26 days of hospital-
ization. The direct annual cost for otherwise healthy children
hospitalized with varicella in Turkey was estimated to be US $396,200.Discussion
Although varicella complications are believed to be rare in
immunologically healthy children, related hospitalizations have
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Fig. 1 – Number of hospitalized varicella cases according to months of the year.
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[2,21]. Of the 24,488 varicella-related hospitalizations during
2000-2006 in the United States, 70% were among healthy persons
with no contraindications for vaccination [22]. Similarly, we
noted that 80% of the children with varicella who were hospi-
talized during the study period at BEH had no underlying
diseases. Carapetis et al. [2] reported that immunocompromised
patients with varicella were admitted earlier in their illness and
had lower complication rates than did otherwise healthy
patients. For this reason, we conducted a detailed examination
of hospitalizations for varicella only in previously healthy chil-
dren. We estimated that hospitalizations due to varicella in
otherwise healthy children have an incidence of 7.7/100,000. ATable 2 – Reasons for hospitalization in children
with varicella.
Cause n (%)
Complications 147 (79)
Skin, mucosa and soft tissue infections 48 (25.8)
Pyoderma 25
Cellulitis 12
Abscess 5
Cervical lymphadenitis 2
Stomatitis 4
Neurologic 44 (23.7)
Cerebellar ataxia 19
Convulsion 17
Meningoencephalitis 5
Papilloedema, optic neuritis 1
Pneumonia 32 (17.2)
Other 23 (12.3)
Hematologic (thrombocytopenia) 7
Sepsis 8
Upper respiratory tract infection 4
Arthritis 2
Gastrointestinal 2
Other causes 39 (21)
Ageo2 months 21
Fever 8
Generalized skin lesions 3
Poor feeding 3
Poor general appearance 2
Total 186 (100)multicenter study in Turkey also showed that 73.3% of hospi-
talized patients were previously healthy [23]. The estimated
overall incidence was 5.29 to 6.89/100,000 in all children aged 0
to 15 years; therefore, considering that hospitalized patients
constitute 1% of all cases of varicella, the overall incidence of
varicella was estimated as 466 to 768/100,000 [23].
The median age of children hospitalized with varicella-related
complications in the United Kingdom and Ireland was reported as
3 years [5]. In our study, children hospitalized for varicella tended
to be younger; indeed, 47.6% of the patients in our study were 1
year or younger. Seroprevalence studies in Turkey have shown
that after the decline in maternal antibodies present in the
bloodstream at birth, seropositivity rates for VZV were low until
the end of the ﬁrst year (i.e., 16.6%) and gradually increased to
41.2% at age 5 years [24,25]. Protection of children younger than 1
year, however, can be achieved only by increased herd immunity
that is established via a widespread vaccination program because
the vaccine is not recommended in children younger than 1 year.
A multicenter study in France demonstrated a strong inverse
correlation between levels of circulating anti-VZV maternal anti-
bodies in full-term infants and the occurrence of varicella com-
plications in children who contract the disease at age younger
than 1 year [26]. During the ﬁrst 3 months of life, maternal
antibodies against VZV protect most infants, and unless this
immunity is absent, newborns with mild chickenpox should not
require antiviral therapy [27]. In our study population, we
identiﬁed 21 patients aged 14 days to 2 months who were
hospitalized solely for varicella without any complications, and
most of them received antiviral therapy. This indicates that
many physicians still view the disease as a serious illness during
early infancy.
The majority of varicella complications identiﬁed in our study
were bacterial superinfections, which is similar to the ﬁndings of
previous studies [6,21]. Staphylococcus aureus and group A β-
hemolytic streptococci are the main pathogens responsible for
bacterial complications related to varicella [28,29]. Pathogens
were isolated from cultures of tissue samples in only ﬁve of our
study patients (i.e., two had coagulase-negative staphylococci
and one had α-hemolytic streptococci from blood cultures,
whereas one had methicillin-sensitive S. aureus from abscess
material, respectively). The low yield of microorganisms in our
study is likely caused by insufﬁcient culturing practices that must
be improved in future studies and treatment of patients with
varicella.
Neurological complications were the second most common
complication in patients who were hospitalized for varicella in
P<0.05
(hematologic, sepsis, upper respiratory 
tract  infection, arthritis, gastrointestinal)
Fig. 2 – Distribution of complications according to age of the patients.
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complications did not usually result in permanent sequelae, they
could lead to prolonged hospital stays and other indirect costs.
The indirect costs from absenteeism and loss of associated
productivity are more important than the direct health care costs
[31]. The proportion of indirect costs in the total cost of varicella
was reported to range from 42% to 98% in different sudies [32].
The highest percentage reported by Lieu et al. [33] was explained
by the inclusion of the cost of death or prolonged disability
resulting from the disease. Only direct costs were evaluated in
our study.
The costs of varicella-related hospitalizations may vary
according to the epidemiologic features, management strat-
egies of the disease, and the type of complications. Zhou et al.
[17] estimated that in 2006, the direct per case medical cost of
hospitalization for uncomplicated varicella, varicella pneu-
monia, and varicella encephalitis was US $3,317, US $4,213,
and US $12,064, respectively. In Australia, the cost of hospital-
ization for children with varicella was reported to be US $3,272
per case in 2004 [2]. In Spain, hospitalization cost per case wasTable 3 – Total hospital costs (US dollar).
Variable Cost
Mean SD Median Min Max
MED 206 469 108 0 4529
PHY 7 12 4 0 91
LAB 60 80 30 0 515
NC 28 30 20 0 185
HOS 106 73 88 0 696
Total 407 552 283 15 4886
MED, medications; PHY, physicians’ fees for examinations and
consultations; LAB, diagnostic tests and radiological examinations;
NC, nurse care; HOS: bed stay; SD, standard deviation.US $5,113, with the total associated national cost excluding
symptomatic treatment at US $516,531 [34]. We estimated the
direct national cost of varicella-related hospitalizations as US
$396,200 in Turkey. Differences in health service fees such as
hospital and physician costs may explain why hospital care in
Turkey costs less than in the United States, Australia, and
Spain. For Brazil, a country with a socioeconomic background
similar to that of Turkey, Valentim et al. [14] reported that the
hospital cost for a case of varicella was US $439. In China,
inpatient care cost was US $640 per case [35]. In previous
studies, the costs of hospitalizations for varicella were sig-
niﬁcantly higher in children who had underlying diseases
[15,23]. Only otherwise healthy children were included in
our study.
Decisions on vaccine funding are often based on a number of
variables, such as immunogenicity of the vaccine and the cost-
effectiveness of the immunization program. The varicella vaccine
prevents the disease in 85% of immunized children but offers a
97% protection against its most severe forms [36]. Moreover, the
universal two-dose immunization has been shown to be cost-
effective in Western temperate countries [37]. In Brazil, the cost-
effectiveness of a universal vaccination program against varicella
was dependent on the vaccine price and the required number of
doses [14].
In Turkey, one dose of varicella vaccine costs US $45 and
the national birth cohort is 1.2 million. As a preventive
measure, a universal vaccination program will require a large
investment. In this study, however, we conﬁrmed that hospi-
talization in varicella cases contributes to a signiﬁcant cost
burden even in previously healthy children. Our estimates of
costs should contribute to future cost-effectiveness research in
Turkey.Conclusions
In Turkey, a signiﬁcant number of otherwise healthy children
have been hospitalized because of varicella and its complications.
Data gathered about hospitalization expenses provide important
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 2 6 – 2 3 0230knowledge for future cost-effectiveness studies. This information
will, therefore, assist policymakers in decisions about whether to
include the varicella vaccine in childhood vaccination programs.
Rates of complications may provide signiﬁcant background
knowledge for evaluating the impact of vaccinations against
childhood varicella.
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